Chikungunya virus (CHIKV) is an alphavirus responsible for numerous epidemics throughout Africa and Asia, causing infectious arthritis and reportedly linked with fatal infections in newborns and elderly. Previous studies in animal models indicate that humoral immunity can protect against CHIKV infection, but despite the potential efficacy of B-cell-driven intervention strategies, there are no virus-specific vaccines or therapies currently available. In addition, CHIKV has been reported to elicit long-lasting virus-specific IgM in humans, and to establish long-term persistence in non-human primates, suggesting that the virus might evade immune defenses to establish chronic infections in man. However, the mechanisms of immune evasion potentially employed by CHIKV remain uncharacterized. We previously described two human monoclonal antibodies that potently neutralize CHIKV infection. In the current report, we have characterized CHIKV mutants that escape antibody-dependent neutralization to identify the CHIKV E2 domain B and fusion loop “groove” as the primary determinants of CHIKV interaction with these antibodies. Furthermore, for the first time, we have also demonstrated direct CHIKV cell-to-cell transmission, as a mechanism that involves the E2 domain A and that is associated with viral resistance to antibody-dependent neutralization. Identification of CHIKV sub-domains that are associated with human protective immunity, will pave the way for the development of CHIKV-specific sub-domain vaccination strategies. Moreover, the clear demonstration of CHIKV cell-to-cell transmission and its possible role in the establishment of CHIKV persistence, will also inform the development of future anti-viral interventions. These data shed new light on CHIKV-host interactions that will help to combat human CHIKV infection and inform future studies of CHIKV pathogenesis.
Chikungunya virus (CHIKV) is transmitted by mosquito bites and causes a febrile disease that is often characterized by persistent joint pain. Until recently, CHIKV outbreaks were limited to tropical areas of Africa and Asia. However, since 2007, following a large CHIKV epidemic in the Indian Ocean and South-East Asia, CHIKV has also been reported in temperate European regions. As mosquito habitats expand, virus dissemination may become more prevalent, but there are currently no vaccines or CHIKV-specific treatments available. We previously described two human antibodies that potently block cellular CHIKV infection. In the current report, we have characterized CHIKV mutants that escape neutralization to identify sub-domains of the virus envelope which are involved in CHIKV interaction with these antibodies, thereby opening the door for the development of CHIKV-specific sub-domain vaccination strategies. For the first time, we have also demonstrated that CHIKV can be directly transmitted between cells, bypassing transport through the extra-cellular space. This mode of dissemination, which is associated with viral resistance to antibody neutralization, may play a critical role in the establishment of persistent CHIKV infection. Together, these findings will aid the design of new strategies to combat CHIKV infection and will inform future studies of CHIKV pathogenesis.
Citation: Lee CY, Kam Y-W, Fric J, Malleret B, Koh EGL, et al. (2011) Chikungunya Virus Neutralization Antigens and Direct Cell-to-Cell Transmission Are Revealed by Human Antibody-Escape Mutants. PLoS Pathog 7(12): e1002390. doi:10.1371/journal.ppat.1002390
Editor: Mark Heise, University of North Carolina at Chapel Hill, United States of America
Received: July 18, 2011; Accepted: October 5, 2011; Published: December 1, 2011
Copyright: © 2011 Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by Biomedical Research Council, A*STAR, Singapore. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: I have read the journal's policy and have the following conflicts; Chia Yin LEE and Lucile WARTER are inventors in a pending patent.
Chikungunya virus (CHIKV) belongs to the alphavirus genus of the Togaviridae family and is transmitted to humans by Aedes mosquitoes. CHIKV was first isolated in Tanzania in 1952 , with numerous outbreaks subsequently being reported throughout Africa and Asia. Within the last decade, a large CHIKV epidemic has spread from the Indian Ocean islands to India and South-East Asia , . Moreover, cases of CHIKV infection have since been detected both in Italy, in 2007 , , and in France, in 2010 , indicating that CHIKV has now become an infectious threat that is no longer limited to tropical areas.
While CHIKV infection in humans is often associated with only mild clinical symptoms that resolve over 1–2 weeks , there have also been reports of prolonged joint pain , , active and destructive rheumatoid arthritis , and severe encephalopathic events in neonates . Despite the increasing burden of infection in Africa and Asia, and the recent advance of CHIKV into European territories, specific therapies for CHIKV-infected patients are not yet available .
CHIKV exhibits a positive strand RNA genome that encodes 4 non-structural proteins (NSP1–4) and 5 structural proteins: the capsid (C), the E1, E2, and E3 envelope glycoproteins (E2 and E3 are initially synthesized as a single precursor molecule, p62, which is subsequently cleaved), and a small polypeptide molecule, 6K . However, the mature CHIKV virion is comprised only of the C, E1 and E2 proteins, which encapsulate the virus genome –. The E1 and E2 proteins control viral entry into host cells: E1 mediates virus fusion to cell membranes in low pH conditions , , while E2 interacts with a cellular receptor , . These constituent proteins of CHIKV virion mediate virus dissemination, therefore specific targeting of these structures will be key to the future development of effective CHIKV vaccination strategies.
The structure of the E1 protein in alphaviruses has previously been determined using the representative Semliki Forest virus family member , . More recently, the crystal structure of the E1/E2 heterodimer in alphaviruses has also been resolved, both under neutral pH conditions (using CHIKV: ), and at acidic pH (using Sindbis virus: ) thus further clarifying the structural composition of the alphaviruses. The alphavirus E1 ectodomain comprises three separate sub-domains; the N-terminal domain I (central to the 3D structure of E1), the domain II (located at the distal tip of the ectodomain) containing the fusion peptide residues 83–98, and the C-terminal domain III (located close to the viral membrane). The E2 ectodomain also contains three distinct sub-domains; the N-terminal domain A (central to the 3D structure of E2), the domain B - located at the distal tip of the ectodomain and that may interact with a cellular receptor, and the C-terminal domain C (located close to the viral membrane).
Human antibodies isolated from the plasma of a CHIKV convalescent patient have previously been shown to both prevent and cure CHIKV infection in mice , suggesting that neutralizing antibody responses might be capable of efficiently controlling CHIKV infection in humans. Although the brief viremia associated with CHIKV infections is suggestive of rapid viral clearance, several recent reports have instead detected long-lasting CHIKV-specific IgM, suggesting that viral antigens may in fact persist in humans , . Moreover, long-term survival of CHIKV in macrophages has also been reported in non-human primates , indicating that CHIKV might establish chronic infections that evade immune defenses.
Viruses can escape neutralizing antibody responses by undergoing genetic mutations that abolish antibody binding, or by indirect evasion strategies such as cell-to-cell transmission. It is currently unclear whether CHIKV is capable of exploiting these strategies to persist in human hosts.
In this study, we aimed to characterize CHIKV antigens targeted by neutralizing human antibodies to inform the subsequent design of CHIKV-specific sub-domain vaccination strategies. We also sought to identify potential mechanisms of immune evasion that CHIKV might exploit to establish persistent infections in man. We recently identified two human monoclonal antibodies (mAb), designated 5F10 and 8B10, which broadly and potently neutralize CHIKV in vitro . In the current report, we analyzed neutralization-resistant CHIKV mutants to identify the E2 domain B and the fusion loop “groove” as the primary determinants of CHIKV interaction with 5F10 and 8B10, respectively. Furthermore, we provide evidence that CHIKV can be efficiently transmitted from cell to cell in a manner that depends on E2 domain A, and that is associated with resistance to antibody-dependent neutralization. Taken together, these data advance our understanding of CHIKV-human host interactions and will inform future efforts to combat this viral disease.
Selection of CHIKV mutants escaping antibody-dependent neutralization
We recently identified two human mAb designated 5F10 and 8B10, which broadly and potently neutralize CHIKV in vitro (28). In order to identify the neutralization antigens that are targeted by these mAb, we subjected a CHIKV clinical isolate (CHIKV11) to 8 rounds of amplification under the continuous neutralizing pressure of mAb 5F10, 8B10, 5F10+8B10, or an irrelevant isotype-matched control (Irr.IgG1), before isolating viruses CHIK/5F, CHIK/8B, CHIK/5F+8B, and CHIK/Irr, respectively. When assessed in a Plaque Reduction Neutralization Test (PRNT), CHIK/Irr was efficiently neutralized by 5F10 and 8B10, either by each mAb independently, or by both mAb used in combination, whereas CHIK/5F was not neutralized by 5F10 (Figure 1). CHIK/8B and CHIK/5F+8B were less efficiently neutralized by 8B10 and 5F10+8B10 respectively than the CHIK/Irr control (Figure 1). These data indicated that CHIK/5F was resistant to 5F10 neutralizing activity, while CHIK/8B and CHIK/5F+8B were partially resistant to 8B10 and 5F10+8B10 neutralizing mAb.
CHIK/Irr, CHIK/5F, CHIK/8B and CHIK/5F+8B indicate CHIKV rescued from 8 serial cell passages under the continuous mAb pressure of Irr.IgG1, 5F10, 8B10 and 5F10+8B10, respectively. (A) The neutralizing potency of CHIKV-specific mAb was evaluated in PRNT over a concentration range of 1 ng-100 µg/ml. Displayed are the mean and SEM from 3 independent experiments performed in duplicate, with non-linear regression fitting curves. Regression could not be calculated for CHIK/5F due to non convergence. (B) The extrapolated IC50 from 2 or 3 independent experiments are shown, alongside the mean and SEM.
To investigate whether CHIKV resistance to mAb 5F10 and/or 8B10 was associated with specific mutation(s), viral RNA was isolated from each CHIKV mutant and reverse-transcribed into cDNA for sequencing. When compared with the CHIK/Irr control genome, we identified two nucleotide (nt) substitutions within the CHIK/5F genome that resulted in amino acid (aa) changes at positions 82 and 216 in the E2 protein (E2.R82G and E2.V216E). In the CHIK/8B genome, we identified one nt substitution that resulted in an aa change at position 101 in the E1 protein (E1.T101M), and also observed 1 mix of wild-type (wt)/mutated nt, with the mutated nt leading to one aa change at position 12 of E2 (E2.T12I). We detected only one nt substitution in the CHIK/5F+8B genome, which generated the same E2.R82G substitution as previously identified in CHIK/5F genome (Table 1). We did not identify any mutations within the C, E3 or 6K protein-encoding sequences.
Intriguingly, the mutated nts associated with the residue substitutions E1.T101M, E2.T12I, E2.R82G and E2.V216E were also detectable in the polyclonal CHIK/Irr control cDNA preparation (Table 2), although their proportion was extremely low (0.05–0.20% of the total nts at each position). This suggests that minor pre-existing CHIKV quasi-species were amplified under selective pressure from CHIKV-neutralizing mAb.
Key amino acid substitutions in the E1 and E2 proteins that confer CHIKV resistance to antibody-dependent neutralization
To investigate the roles of the different CHIKV mutations in mediating resistance to mAb 5F10 and 8B10, we isolated CHIKV clones that exhibited either single or dual mutations and then further probed their sensitivity to mAb-dependent neutralization.
CHIKV populations were cultured under agarose-medium before 6 individual CHIK/5F, CHIK/8B, or CHIK/5F+8B colonies (or 2 CHIK/Irr control colonies) were isolated for amplification and sequencing. The sequencing data from the plaque-purified CHIKV clones are shown in Table 3. The 6 CHIK/5F-derived clones contained both the E2.R82G and E2.V216E mutations. One of the CHIK/5F-derived clones also contained 2 additional aa substitutions within the E1 trans-membrane domain (T396A and I427T). Five of the CHIK/8B-derived clones contained both the E1.T101M and E2.T12I mutations, while another CHIK/8B-derived clone contained the E1.T101M mutation alone. All 6 CHIK/5F+8B-derived clones contained the E2.R82G mutation. Hereafter, the 5F10-derived clonal viruses are designated 5F/E2.R82G+V216E and 5F/E1.TMm+E2.R82G+V216E, the 8B10-derived virus mutants as 8B/E1.T101M and 8B/E1.T101M+E2.T12I, and the 5F10+8B10-derived virus, as 5F+8B/E2.R82G. The Irr.IgG1-derived clonal virus is designated CHIKwt.
In PRNT assays, mAb 5F10 neutralized 5F/E2.R82G+V216E and 5F/E1.TMm+E2.R82G+V216E far less efficiently than CHIKwt (Figure 2). There were no significant differences between the two mutants, suggesting that neither of the two mutations in E1 had any effect on the neutralization potency of mAb 5F10. Although high concentrations of mAb 5F10 did not neutralize the CHIKV mutant containing E2.R82G alone (5F+8B/E2.R82G) as efficiently as CHIKwt, there was no significant difference in IC50 between 5F+8B/E2.R82G and CHIKwt, suggesting only a minimal effect of the mutation E2.R82G on 5F10-dependent CHIKV neutralization. Together, these data suggest a key role for the E2.V216E mutation in mediating CHIKV resistance to 5F10-dependent neutralization.
CHIKV variants have been labelled according to their residue substitutions and corresponding mAb added to the culture medium during the serial passages. (A) Neutralizing capacities of the mAb against plaque-purified CHIKV were evaluated in PRNT over a concentration range of 1 ng-100 µg/ml. Shown are the mean and SEM from 4 independent experiments performed in duplicate with non-linear regression fitting curves. (B) The calculated IC50 from 3 or 4 independent experiments and mean ± SEM are shown (P-values were calculated using Kruskal-Wallis test and Dunn's post-test, and compare with the IC50 against CHIKwt: *, p<0.05; ***, p<0.001).
In parallel, mAb 8B10 neutralized 8B/E1.T101M less efficiently than CHIKwt (Figure 2), indicating a contribution for the mutation E1.T101M in mediating CHIKV resistance to 8B10-dependent neutralization. However, the viral mutant 8B/E1.T101M was more efficiently neutralized by mAb 8B10 than the dual mutant 8B/E1.T101M+E2.T12I (Figure 2), demonstrating that both the E1.T101M and E2.T12I mutations confer CHIKV resistance to 8B10-dependent neutralization.
Interestingly, the 8B10-derived CHIKV mutants remained efficiently neutralized by mAb 5F10, and vice versa (Figure 2). Thus, the binding sites of 5F10 and 8B10 are most likely different.
As the two mutations in the E1 trans-membrane domain were not associated with resistance to mAb-dependent neutralization, 5F/E1.TMm+E2.R82G+V216E was excluded from further analyses. Although the E2.R82G mutation was not found to be associated with significant resistance to mAb-dependent neutralization in PRNT assay, as this was the only mutation to be selected under dual treatment with mAb 5F10 and 8B10 (Tables 1 and 3), It was hypothesized that this mutation might be associated with a CHIKV immune evasion mechanism which was not detectable by PRNT assay. We therefore retained the 5F+8B/E2.R82G mutant for analysis in subsequent experiments.
E2.V216E and E1.T101M abolish the binding of 5F10 and 8B10 to CHIKV
To clarify the mechanism(s) associated with the neutralization escape mutations, we next analyzed the capacity of mAb 5F10 and 8B10 to bind to clonal CHIKVs (Figure 3).
(A) Analysis of mAb binding to CHIKV-infected cells by immunofluorescence assay. HEK293T cells either non-infected, or infected with the indicated CHIKVs, were probed with mAb 5F10, 8B10, anti-CHIKV plasma, or with irrelevant IgG1. Images were captured at 100× magnification. (B) Quantitative analysis of mAb binding to CHIKV-infected cells by Cellomics ArrayScan. HEK293T cells, either mock infected or infected with the indicated CHIKVs, were probed with mAb 5F10, 8B10, anti-CHIKV plasma, or with irrelevant IgG1. Images were captured at 10× magnification. Displayed are mean fluorescent intensity (MFI) and SEM from 3 independent experiments performed in quadruplicate (P-values were calculated by Kruskal-Wallis test and Dunn's post-test, and compare with the MFI of CHIKwt-infected cells: *, p<0.05; **, p<0.01; ***, p<0.001). (C) ELISA analysis of mAb binding to plaque-purified CHIKV particles. ELISA plates were coated with 104 UV-inactivated CHIKV particles, prior to being incubated with mAb (0.1 ng-100 µg/mL). Bound mAb were detected using HRP-conjugated goat anti-human IgG and TMB substrate. The OD was measured at 450 nm. Shown are mean and SEM from 3 independent experiments performed in duplicate.
Binding tests performed on CHIKV-infected cells (Figure 3A and 3B) and on CHIKV particles (Figure 3C) showed that the binding of 5F10 to 5F/E2.R82G+V216E was drastically impaired, whereas 5F10 efficiently bound the single mutant 5F+8B/E2.R82G. The binding of 8B10 to both 8B/E1.T101M and 8B/E1.T101M+E2.T12I was severely impeded. Interestingly, 5F10-derived mutated viral particles remained bound by 8B10 and vice versa (Figure 3C), confirming that mAb 5F10 and 8B10 exhibit distinct epitope specificities. However, binding assays performed on infected cells showed that 5F10-derived viruses were less efficiently bound by 8B10 when compared with CHIKwt (Figure 3A and 3B). These data are consistent with our previous suggestion that the target epitope for 8B10 was likely to be conformation-dependent . It is therefore possible that, while expressed in infected cells and under experimental conditions used for the binding test on infected cells, the 8B10 epitope is indirectly modified by substitution of distantly located residues, such as E2.82 or E2.216.
Taken together, these data demonstrate that mutations E2.V216E and E1.T101M abolish the binding of mAb 5F10 and 8B10 to CHIKV, respectively.
Structural location of key amino acid residues in the alphavirus E1/E2 glycoprotein
To further clarify the CHIKV domains involved in virus interaction with mAb 5F10 and 8B10, we used Chimera software to locate residues E1.101, E2.12, E2.82 and E2.216 within the CHIKV E1/E2 heterodimer for which the crystal structure was recently resolved under neutral pH conditions  (Figure 4).
Based on structural data retrieved from protein database records, the 3D organization of E1 (pale yellow), E2 (white), and the E1 fusion loop (pink) are shown for 3N44 under neutral pH conditions. (A) Front view of E2 with the location of E2.216 (green) and E2.82 (orange). (B) Back left view of E2 and E1 with the location of E2.12 (blue) and E1.101 (red).
The E2.82 residue is exposed at the surface of the E2 domain A (Figure 4A), while the E2.216 residue is found at the tip of the E2 domain B (Figure 4A), in a position easily accessible to antibody binding.
The E1.101 residue is located within the E1 domain II next to the fusion loop (Figure 4B), suggesting that mAb 8B10 might target the fusion peptide itself. However, under neutral pH conditions, the exposed surface of the native viral particle is largely comprised of the E2 domains A and B, whereas the E1 protein remains concealed beneath the E2 protein, and its fusion peptide fits into a “groove” which is delineated by E2 domains A and B . Therefore, under neutral pH conditions, E1.101 is unlikely to be accessible to antibody binding.
The E2.12 residue, which is involved in resistance to 8B10-dependent neutralization together with E1.101 (Figure 2), is located within the E2 domain A, directly above the “groove” which incorporates E1.101 (Figure 4B).
Noteworthy, under acidic pH conditions, the alphavirus domain B becomes disordered and releases the fusion loop . Interestingly, on the E2/E1 spatial arrangement of Sindbis virus (closely related with CHIKV) resolved under acidic pH conditions , the residues E1.101 and E2.12 are located on the internal side of the opened “groove”, facing each other (Figure 5). This suggests that after virus internalization into host cell and within the acidic endosomal compartment, the residues E1.T101 and E2.T12 (corresponding to Sindbis virus E1.S101 and E2.T9) may become more accessible to antibodies and come together to form a transitional epitope.
Indicated residues were located based on structural data retrieved from protein data base records (3MUU, under acidic pH conditions).
Taken together, these structural data strongly suggest that the 5F10 epitope is located at the tip of the CHIKV E2 domain B which contains the E2.216 residue. While the 8B10 target antigen remains somewhat ambiguous, our data suggest that this antibody may recognize a transitional epitope closely associated with the CHIKV fusion peptide.
Fitness characteristics of the CHIKV E2.R82G mutant suggest viral cell-to-cell transmission
The alignment of available CHIKV E1 and E2 protein sequences obtained from GeneBank (data not shown) indicated that all published CHIKV variants contain the residues E1.T101, E2.T12, E2.V216 and E2.G82, except for one strain: TSI-GSD-218, which contains E2.I12 and E2.R82. Thus, among the mutations selected here, E1.T101M, E2.T12I and E2.V216E clearly modify highly conserved CHIKV residues, while E2.R82G instead restores a highly conserved viral residue. These data indicate that the CHIKV11 isolate used in the current study is atypical with regards to the E2.82 residue, and suggest an important role for the E1.T101, E2.T12, E2.G82 and E2.V216 residues in the CHIKV life cycle. Therefore, the substitution of these conserved residues was expected to modify CHIKV fitness, and thus, we next investigated fitness characteristics of 5F10/8B10-resistant CHIKV escape mutants.
We first assessed the in vitro extra-cellular spreading of the mAb-resistant CHIKV mutants. Vero cells were infected with clonal CHIKVs, and viral titer was next determined by Plaque Assay and expressed as the number of Plaque Forming Units (PFU) per mL of cell culture supernatant. Over the 48 h growth period, all CHIKV escape mutants led to significant decreases in PFU number, when compared with CHIKwt (Figure 6A). These results demonstrate that CHIKV variants which escape 5F10- and/or 8B10-dependent neutralization are impaired in extra-cellular viral spreading in vitro.
(A) Vero cells were infected with plaque-purified CHIKV (MOI = 0.1). The number of PFU within the supernatants was determined by Plaque Assay at various times post-infection. Shown are mean and SEM from 3 independent experiments performed in duplicate. (B) Shown are typical plaque patterns by crystal violet staining at 12 h post-infection. (C) AGR129 mice were inoculated with plaque-purified CHIKV (103 PFU). PBS-inoculated mice were used as negative controls. Mice were observed every 12 h to determine post-infection survival. Shown are the survival curves derived from 3 independent experiments (CHIKV, n = 10; Mock infected, n = 6). P-values were determined by Grehan-Breslow-Wilcoxon test and compare CHIKV mutants with CHIKwt. (D) Mice were inoculated with CHIKwt or 5F+8B/E2.R82G (103 PFU) and the CHIKV load in serum and liver was quantified 48 h post-infection by TCID50. Shown are mean and SEM for 5 mice per group. P-values were determined using Mann-Whitney test (*, p<0.05). (E) At 48 h post-infection, the amount of CHIKV (-)RNA in liver was determined by quantitative RT-PCR. Shown are mean and SEM for 5 mice per group. P-values were determined using Mann-Whitney test (**, p<0.01).
We next investigated the in vivo fitness of the CHIKV neutralization-escape mutants. AGR129 immuno-compromised mice  were used to determine survival after infection with the different clonal CHIKVs (Figure 6C). Mice infected with 8B/E1.T101M were indistinguishable from control mice infected with CHIKwt, suggesting that the E1.T101M mutation does not interfere with CHIKV fitness in vivo. In contrast, death among mice infected with 8B/E1.T101M+E2.T12I was delayed, when compared with mice infected with CHIKwt, suggesting that the E2.T12I mutation impairs CHIKV fitness in vivo. Interestingly, mice infected with 5F+8B/E2.R82G or 5F/E2.R82G+V216E died significantly earlier than those infected with other CHIKV variants. However, no difference was observed between mice infected with either 5F+8B/E2.R82G or 5F/E2.R82G+E2.V216E, suggesting that the E2.R82G mutation is entirely responsible for the rapid post-infection mortality, and that the E2.V216E mutation does not alter in vivo CHIKV fitness.
Mice were next infected with either CHIKwt or 5F+8B/E2.R82G and viral load was determined in serum and liver at 48 h post-infection (Figure 6D), alongside quantification of CHIKV (-) RNA in liver (Figure 6E). In both liver and serum, viral load of 5F+8B/E2.R82G was significantly higher than that of CHIKwt, with the largest difference (~1000-fold) being observed in serum (Figure 6D). Likewise, the number of 5F+8B/E2.R82G (-) RNA copies in liver was ~10-fold higher than for CHIKwt (Figure 6E). These data demonstrated that 48 h post-infection, the level of 5F+8B/E2.R82G replication was higher than that of CHIKwt. Moreover, a previous study in an alternative murine model of immunodeficiency reported that CHIKV is detected in the liver prior to being detected in the serum . Therefore, our data suggest that 5F+8B/E2.R82G spreads faster in vivo than CHIKwt, since CHIKwt load was reduced in serum compared with liver, while the 5F+8B/E2.R82G load was comparable in both tissues (Figure 6D). The enhanced in vivo fitness of 5F+8B/E2.R82G supports an important role for the E2.G82 residue in CHIKV life cycle, which may explain the high conservation of this residue among CHIKV strains described as of now.
Since measuring the relative size of virus-induced plaques is commonly performed to monitor viral cell-to-cell transfer –, we were intrigued to observe that 5F+8B/E2.R82G and 5F/E2.R82G+V216E gave rise to bigger plaques compared with alternative CHIKV variants (Figure 6B). This “big plaques” phenotype, together with the impaired in vitro extra-cellular viral spreading (Figure 6A), suggested that CHIKV might disseminate directly from cell to cell, in a manner induced or enhanced by the mutation E2.R82G. Interestingly, the rapid in vivo spreading of 5F+8B/E2.R82G when compared with CHIKwt (Figure 6C–6E), further suggested an E2.R82G-associated CHIKV cell-to-cell transmission, as this mode of dissemination is considered to be faster than extra-cellular transmission .
CHIKV cell-to-cell transmission is enhanced by E2.R82G
Direct cell-to-cell transmission was previously proposed to occur during CHIKV infection in vitro , but formal demonstration of this mode of dissemination has been lacking. To address this possibility, unlabeled HEK293T cells were infected with either CHIKwt or 5F+8B/E2.R82G. Ten hours post-infection, the infected cells (producer cells) were co-cultured with CFSE-labeled non-infected HEK293T cells (target cells), in the presence or absence of mAb 8B10. After 0 h and 16 h of co-culture, the number of CHIKV-infected cells was determined by flow-cytometry (Figure 7A). By 16 h, the majority of target cells (47.0% and 51.1% for CHIKwt and 5F+8B/E2.R82G, respectively) were CHIKV-infected when cultured without mAb 8B10. Interestingly, even in the presence of 8B10 neutralizing pressure, the mean proportion of infected target cells was 11.7% for CHIKwt and 20.6% for 5F+8B/E2.R82G. We therefore hypothesized that these cells had either been infected by direct CHIKV cell-to-cell transmission, or by 8B10-resistant extra-cellular CHIKV particles. However, in the presence of mAb 8B10, extra-cellular CHIKV particles were undetectable in the 5F+8B/E2.R82G-derived supernatants, and only an extremely low titer was measured in CHIKwt-derived supernatants (Figure 7B), demonstrating that, under 8B10 neutralizing pressure, target cells infection resulted from CHIKV direct cell-to-cell transmission. Moreover, the significant higher percentage of infected target cells detected with 5F+8B/E2.R82G as compared with CHIKwt indicates that CHIKV cell-to-cell transmission is enhanced by the E2.R82G mutation.
CHIKV-infected HEK293T cells (producer cells) were co-cultured with CFSE-labeled naïve HEK293T cells (target cells) in the absence or presence of mAb 8B10. (A) The number of infected cells was quantified by flow-cytometry either immediately (T = 0 h), or after 16 h of co-culture (T = 16 h). Above each panel are shown the mean number of infected producer (T = 0 h) or target (T = 16 h) cells alongside the SEM (5 independent experiments performed in duplicate). P-values were determined using Wilcoxon test, and compare CHIKwt and 5F+8B/E2.R82G infectivity (*, p<0.05). (B) After 16 h of co-culture, the number of extra-cellular CHIKV particles within the supernatants was determined by Plaque Assay. Shown are mean and SEM from 5 independent experiments performed in duplicate.
To further confirm direct cell-to-cell transmission of CHIKV, some co-cultures were visualized by confocal microscopy. For both CHIKwt and 5F+8B/E2.R82G, in the absence of mAb 8B10, CHIKV staining was detected uniformly on the cell surface, whereas, under 8B10 neutralizing pressure, CHIKV staining was strongly polarized and virus was often detected in areas of cell-cell contact (Figure 8). These data strongly suggest that, when the virus is subjected to antibody dependent-neutralizing pressure, CHIKV dissemination occurs by direct cell-to-cell transfer at areas of cell membrane contact. Although these results further show that CHIKwt can also disseminate by direct cell-to-cell transfer, as less CHIKV-specific staining was detected in target cells with CHIKwt, when compared with 5F+8B/E2.R82G, these data confirm that the E2.R82G mutation enhances CHIKV cell-to-cell transmission.
CHIKV-infected HEK293T cells were co-cultured with CFSE-labeled naïve HEK293T cells (green) in the absence or presence of mAb 8B10. After 16 h of co-culture the cells were fixed, permeabilized, and stained for alphavirus expression (Alexa 647, red). Newly infected target cells appear orange. Magnification: ×40 or ×80.
We previously demonstrated potent in vitro neutralization of CHIKV using human mAbs 5F10 and 8B10 . In the current report, we have characterized CHIKV variants that escape 5F10 and/or 8B10-dependent neutralization to identify the CHIKV E2 domain B and the fusion loop “groove” as the primary determinants of CHIKV interaction with these neutralizing antibodies. We have also demonstrated CHIKV cell-to-cell transmission, which involves the E2 domain A, and may represent a route by which the virus evades antibody-dependent neutralization.
Escape mutants have previously been described for three members of the alphavirus family; Sindbis virus , –, Ross River virus  and Venezuelan Equine Encephalitis virus –. Several neutralization escape mutations have been identified within the alphavirus E2 domain A ,  and domain B , , , as well as within the E1 domain II . However, CHIKV mutants that escape antibody-dependent neutralization have not previously been reported, and the alphavirus residues E1.101 and E2.12 were not previously shown to be determinants of neutralizing antibodies binding. Consistent with the current report, the E2.216 residue has previously been identified as being involved in major B-cell neutralization epitopes for Sindbis virus, Ross River virus and Venezuelan Equine Encephalitis virus , , , suggesting that the region covering the E2.216 residue within the E2 domain B is an important antigenic domain shared by several alphaviruses. Of note, Coffey and Vignuzzi recently described mutations that affect the CHIKV E2 residues 229–234 as being due to selective pressure from neutralization . These mutations affected the C-terminal end of the E2 domain B, as well as the ß-ribbon connector which links the domain B to the domains A and C , . Although these mutations were not formally shown to be responsible for CHIKV resistance to neutralization , their location is consistent with a crucial role for the CHIKV E2 domain B in virus-neutralizing antibody interactions.
Our results strongly suggest that the 5F10 mAb epitope is located at the tip of the CHIKV E2 domain B, while 8B10 might recognize a transitional epitope, close to the fusion loop, which is likely to be exposed under acidic pH conditions. Interestingly, in addition to the disordering of the alphavirus envelope at acidic pH, virus binding to a host cellular receptor is believed to induce pH-independent shifting of the E2 domain B, leading to exposure of transitional epitopes prior to virion internalization , , , . We therefore speculate that 8B10 mAb epitope might be accessible to antibody binding before virus internalization into host cell but upon CHIKV binding to a cellular receptor.
Based on their proposed epitope specificity, we speculate that 5F10 and 8B10 inhibit viral entry and fusion to the cell membrane, respectively. However, it has also been suggested that antibodies which target the E2 domain B might also affect the viral-cell fusion step, possibly by inhibiting domain disordering and fusion loop exposure . Thus 5F10 might alternatively inhibit virus-cell membrane fusion instead of overtly inhibiting viral entry.
Although RNA viruses are usually prone to high nucleotide sequence evolution due to their lack of a proofreading polymerase –, arboviruses seem less likely to genome modifications, as evidenced by their high rate of nucleotide sequence conservation over the time. This may be due to their lifecycle requirement to replicate in two taxonomically distinct hosts –. Thus, most mutations which occur during arboviruses replication appear to impair viral fitness. In line with these observations, we showed that modification of the conserved CHIKV residues E1.T101, E2.T12, E2.G82, and E2.V216 is associated with reduced viral fitness in vitro and/or in vivo.
After 8 cycles of neutralization/amplification, only partial CHIKV resistance to mAb 8B10 or 5F10+8B10 was observed. We then performed 5 additional rounds of neutralization/amplification while using increasing concentrations of mAb. However, even after 13 neutralization/amplification rounds under mAb selective pressure, we did not manage to select a CHIKV population fully resistant to 8B10 or 5F10+8B10 (data not shown). It is likely therefore that the mutation(s) required to fully escape 8B10 and 5F10+8B10 mAb give(s) rise to viruses that are unable to replicate robustly.
Cell-to-cell virus transmission is faster than extra-cellular spreading and enables viruses to evade the immune response , , . Herpesviruses, flaviviruses, paramyxoviruses, poxviruses, retroviruses and rhabdoviruses have already been shown to employ this cell-associated infection route, either exclusively, or in parallel with extra-cellular viral dissemination , . Cell-to-cell transmission seems to be limited to enveloped viruses which exit at the plasma membrane either by budding or by exocytosis, whereas lytic viruses disseminate only by extra-cellular transmission , . Despite their biological and structural characteristics making them prone to cell-associated dissemination, alphaviruses have not previously been shown to transfer directly between cells. Interestingly, in an earlier report, direct CHIKV transmission between cells was postulated as a mechanism of antibody escape since the virus could be detected in cultured cells despite the presence of anti-CHIKV serum . However, the presence of newly-infected cells was not demonstrated.
We demonstrate in this report, for the first time, CHIKV direct cell-to-cell transmission, and further show that this mode of dissemination is enhanced by the E2.R82G mutation. Interestingly, as the alignment of available CHIKV E2 protein sequences obtained from GeneBank (data not shown) revealed that the majority of CHIKV variants contain the residue E2.G82 (and not E2.R82), we speculate that direct cell-to-cell transmission is commonly used by CHIKV to disseminate in the presence of extra-cellular neutralizing antibodies. However, this remains to be shown with CHIKV isolates containing the residue E2.G82.
Viruses have evolved various mechanisms to disseminate from cell to cell. Pre-existing cell-cell contacts may be exploited, or virus-induced new contacts can be established between infected and uninfected target cells. , , . The confocal microscopy images presented in the current report suggest that CHIKV may use pre-existing cell-cell contacts, possibly tight junctions, to transfer directly between cells. Further studies are now warranted to precisely characterize the mechanism of CHIKV cell-to-cell transmission.
The fact that CHIKV cell-to-cell transmission is enhanced by E2.R82G, suggests the involvement of the CHIKV E2 domain A in this mode of dissemination. Interestingly, the E2 domain A of both Venezuelan Equine Encephalitis virus and Sindbis virus has previously been shown to contain residues that are important for virus binding to cells, notably to heparan sulfate located at the cell surface , –. In this context, we speculate that the mutation E2.R82G may similarly enhance CHIKV binding to the target cell.
For the first time, we have identified CHIKV envelope domains that are recognized by human neutralizing immune responses, and we have been able to demonstrate direct cell-to-cell transmission of CHIKV. This mode of dissemination, which protects CHIKV from neutralizing host antibodies, might play an important role in establishment of CHIKV persistence. These findings advance our understanding of CHIKV-human host interactions and will aid the rational design of future domain-based vaccines against CHIKV, as well as inform further studies of CHIKV pathogenesis.
Materials and Methods
This study was carried out in strict accordance with the guidelines of the Agri-Food and Veterinary Authority (AVA) and the National Advisory Committee for Laboratory Animal Research (NACLAR) of Singapore. All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Biological Research Center, Biomedical Sciences Institutes, A*STAR, Singapore (IACUC number: #100515).
Cells, antibodies and viruses
Vero cells (ATTC CCL-81) and HEK293T cells (ATCC CRL-N268) were cultured in DMEM-10% FCS (Gibco-Invitrogen). The CHIKV-neutralizing human mAb 5F10 and 8B10, the irrelevant human mAb HA4 (referred as Irr.IgG1), and the CHIKV isolate CHK/Singapore/11/2008 (referred as CHIKV11) have been described previously .
Selection of 5F10 and 8B10-resistant CHIKV mutants
CHIKV11 (200 PFU) was incubated for 1 h at 37°C with 100 ng/ml 5F10 and/or 8B10 in DMEM-10% FCS. HEK293T cells were then incubated at 37°C for 1.5 h with mAb/CHIKV mixtures, prior to being further cultured in DMEM-10% FCS supplemented with additional mAb as before for 2 days. Cell supernatants were then collected and their infectious viral titer was determined by Plaque Assay; 200 PFU of rescued virus was subjected to a second round of neutralization/amplification in the presence of the same antibodies as employed in previous steps. Eight neutralization/amplification rounds were performed in total.
Vero cells were infected for 1.5 h with CHIKV (10 PFU/well) before being washed with PBS and cultured in DMEM-0.25% agarose for 2 days. Individual CHIKV colonies were then selected through the agarose layer and amplified separately in Vero cells. Plaque-purified clonal CHIKV genomes were then sequenced.
Viral RNA was extracted from 140 µl supernatant from CHIKV infected-cells using the QIAamp Viral RNA Mini kit (Qiagen). For each viral RNA, two independent full-length cDNAs were synthesized using random hexamers and SuperScript III First-Strand kit (both from Invitrogen). Purified cDNAs were PCR-amplified using Taq PCR Master Mix Kit (Qiagen) and several primer pairs designed to cover the C-E1 CHIKV polyprotein encoding sequence and to generate ~1000 bp-long overlapping PCR fragments. PCR fragments were sequenced (Aitbiotech) and results were analyzed using Lasergene 7 software.
A 200 bp cDNA library was synthesized from 56 ng of extracted CHIK/Irr RNA using the mRNA-seq Sample Prep Kit (Illumina) according to the manufacturer's instructions. The cDNA library was then sequenced using the Illumina GAIIX genome analyzer (Next Generation Sequencing Core facility, Genomic Institute of Singapore) at the coverage of 67436×. Unique reads were subsequently aligned with the consensus sequence encoding CHIKV11 structural proteins (C-E1) using the Burrows-Wheeler aligner, and site-specific nucleotide frequencies were determined using SAMtools Pileup.
Plaque Reduction Neutralization test and mAb potency
The Plaque Reduction Neutralization test and determination of mAb potency were performed as previously described .
Immunofluorescence Assay: HEK293T cells were infected with CHIKV and then fixed as previously described . One µg/ml mAb or human anti-CHIKV polyclonal plasma (1:200) was added to either CHIKV-infected or non-infected cells for 1 h at 37°C. Antibody binding was detected by addition of 2 µg/ml Alexa-488-labeled mouse anti-human IgG (Invitrogen) followed by fluorescence microscopy (NIKON ECLIPSE TS 100) at 100× magnification. Alternatively, mAb binding to CHIKV-infected cells was quantified using a Cellomics HCS Reader (Cellomics ArrayScan, Thermo Fisher Scientific): HEK293T cells were infected with CHIKV as previously described . At 24 h post-infection, the cells were washed and fixed overnight with 4% paraformaldehyde. One µg/ml mAb or human anti-CHIKV polyclonal plasma (1:200) was added to CHIKV-infected or non-infected cells for 1 h at 37°C. Antibody binding was detected by addition of 10 µg/ml Alexa-488-labeled mouse anti-human IgG (Invitrogen). Cell nuclei were visualized using DAPI staining and images were captured at 10× magnification.
In some experiments, 96-well plates were coated with UV-inactivated plaque-purified CHIKVs (104 PFU/well) for analysis by ELISA. A range of mAb concentrations (0.1 ng-10 µg/mL) were added to the wells for 1 h at RT. Bound mAb were detected using HRP-conjugated goat anti-human IgG (Jackson ImmunoResearch), followed by incubation with 3,3′,5,5′-tetramethybenzidine substrate (Sigma). The reaction was stopped by addition of HCl (1 M) and absorbance was measured at 450 nm using the TECAN Infinite M200 Monochromator Microplate Reader (TECAN).
In vitro viral fitness analysis
Vero cells were infected with plaque-purified CHIKV mutants (MOI = 0.1) for 1.5 h prior to being cultured in DMEM-10% FCS. The number of PFU in each supernatant was determined by Plaque Assay at various times post-infection.
In vivo experiments
AGR129 mice (IFN-α/ß/γR−/−/− and RAG-2 deficient, ) were used at 8–12 weeks of age and were inoculated intravenously with 103 CHIKV PFU diluted in 200 µl PBS (or with PBS-alone for control mice). In survival experiments, mice were observed at 12 h intervals thereafter. For viral load quantification, mice were bled at 48 h post-infection, prior to sacrificing them and liver harvesting. Viral load in sera and homogenized liver supernatants were determined by measurement, using Vero cells, of tissue cytopathic infectious dose 50 (TCID50) expressed as TCID50/mL and TCID50/g, respectively. In parallel, total RNA was extracted from 1 g of liver using TRI reagent (Sigma) according to the manufacturer's instructions. To quantify CHIKV (-)RNA copies, 3.6 ng total RNA extracted from liver was subjected to qRT-PCR as previously described .
HEK293T cells were infected with CHIKV for 1.5 h (MOI = 0.1), then washed and cultured in DMEM-10% FCS. At 10 h post-infection, naïve “target” HEK293T cells were labeled with 10 µM CFSE (Sigma) and 3×105 labeled “target” cells were co-seeded into 12-well plates with 3×105 extensively washed infected or non-infected “producer” cells. The cells were then co-cultured in DMEM-10% FCS, supplemented or not with 200 µg/mL 8B10. At 0 h and 16 h post-co-culture the cells were harvested, washed and fixed/permeabilized (BD Cytoperm/Cytofix, BD Biosciences), prior to intracellular staining with 5 µg/mL mouse IgG2a anti-alphavirus (3581) (Santa Cruz Biotechnology) followed addition of 4 µg/mL Alexa 647-conjugated goat anti-mouse IgG (Invitrogen). The proportion of infected cells was then determined by flow-cytometry (FACSCalibur, BD Biosciences). Cell supernatants were also collected in parallel after 16 h co-culture for analysis by Plaque Assay to quantify infectious extra-cellular CHIKV. Alternatively, at 14 h post-infection, 105 HEK293T cells were seeded into μ-Slide 8 well plates (Ibidi) with 105 CFSE-labeled uninfected cells and then cultured as described above. After 16 h of co-culture the cells were washed with PBS, fixed with PBS-4% paraformaldehyde and then permeabilized in PBS-0.5% Triton X-100. The permeabilized cells were then stained with 3 µg/mL mouse IgG2a anti-alphavirus (3581) followed by addition of 3 µg/mL Alexa 647-conjugated goat anti-mouse IgG (Invitrogen). ProLong Gold (Invitrogen) was added to the wells and fluorescence was analyzed using an Olympus FV1000 confocal microscope at ×40 magnification (or at ×80 in highlighted panels).
Data were analyzed using GraphPad Prism 5. The specific statistical tests used are indicated in the respective figure legends.
We thank Mark Suter (University of Zurich) for providing AGR129 mice. We are very grateful to Alessandra Nardin (Singapore Immunology Network, BMSI, A*STAR, Singapore) and Annette Martin (Institut Pasteur, Paris, France) for their critical reading of the manuscript, and to Jean-Pierre Abastado and Sebastien Bertin-Maghit (both from Singapore Immunology Network, BMSI, A*STAR, Singapore) for helpful discussions. We are grateful to Lucy Robinson and Neil McCarthy for manuscript editing.
Conceived and designed the experiments: CYL, JF, BM, LR, LFPN, LW. Performed the experiments: CYL, YWK, JF, BM, EGLK, WH, LW. Analyzed the data: CYL, YWK, JF, BM, EGLK, CP, WWLL, LR, CIW, LFPN, LW. Contributed reagents/materials/analysis tools: CL, RTPL. Wrote the paper: LW.
- 1. Robinson MC (1955) An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features. Trans R Soc Trop Med Hyg 49: 28–32.
- 2. Charrel RN, de Lamballerie X, Raoult D (2007) Chikungunya outbreaks–the globalization of vectorborne diseases. N Engl J Med 356: 769–771.
- 3. Her Z, Kam YW, Lin RT, Ng LF (2009) Chikungunya: a bending reality. Microbes Infect 11: 1165–1176.
- 4. Enserink M (2007) Infectious diseases. Chikungunya: no longer a third world disease. Science 318: 1860–1861.
- 5. Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, et al. (2007) Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet 370: 1840–1846.
- 6. Grandadam M, Caro V, Plumet S, Thiberge JM, Souares Y, et al. (2011) Chikungunya virus, southeastern france. Emerg Infect Dis 17: 910–913.
- 7. Staples JE, Breiman RF, Powers AM (2009) Chikungunya fever: an epidemiological review of a re-emerging infectious disease. Clin Infect Dis 49: 942–948.
- 8. Borgherini G, Poubeau P, Jossaume A, Gouix A, Cotte L, et al. (2008) Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island. Clin Infect Dis 47: 469–475.
- 9. Soumahoro MK, Gerardin P, Boelle PY, Perrau J, Fianu A, et al. (2009) Impact of Chikungunya virus infection on health status and quality of life: a retrospective cohort study. PLoS One 4: e7800.
- 10. Bouquillard E, Combe B (2009) A report of 21 cases of rheumatoid arthritis following Chikungunya fever. A mean follow-up of two years. Joint Bone Spine 76: 654–657.
- 11. Gerardin P, Barau G, Michault A, Bintner M, Randrianaivo H, et al. (2008) Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La Reunion. PLoS Med 5: e60.
- 12. Michault A, Staikowsky F (2009) Chikungunya: first steps toward specific treatment and prophylaxis. J Infect Dis 200: 489–491.
- 13. Strauss JH, Strauss EG (1994) The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 58: 491–562.
- 14. Khan AH, Morita K, Parquet Md MC, Hasebe F, Mathenge EG, et al. (2002) Complete nucleotide sequence of chikungunya virus and evidence for an internal polyadenylation site. J Gen Virol 83: 3075–3084.
- 15. Simizu B, Yamamoto K, Hashimoto K, Ogata T (1984) Structural proteins of Chikungunya virus. J Virol 51: 254–258.
- 16. Kielian M, Helenius A (1985) pH-induced alterations in the fusogenic spike protein of Semliki Forest virus. J Cell Biol 101: 2284–2291.
- 17. White J, Helenius A (1980) pH-dependent fusion between the Semliki Forest virus membrane and liposomes. Proc Natl Acad Sci U S A 77: 3273–3277.
- 18. Dubuisson J, Rice CM (1993) Sindbis virus attachment: isolation and characterization of mutants with impaired binding to vertebrate cells. J Virol 67: 3363–3374.
- 19. Strauss EG, Stec DS, Schmaljohn AL, Strauss JH (1991) Identification of antigenically important domains in the glycoproteins of Sindbis virus by analysis of antibody escape variants. J Virol 65: 4654–4664.
- 20. Gibbons DL, Vaney MC, Roussel A, Vigouroux A, Reilly B, et al. (2004) Conformational change and protein-protein interactions of the fusion protein of Semliki Forest virus. Nature 427: 320–325.
- 21. Lescar J, Roussel A, Wien MW, Navaza J, Fuller SD, et al. (2001) The Fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. Cell 105: 137–148.
- 22. Voss JE, Vaney MC, Duquerroy S, Vonrhein C, Girard-Blanc C, et al. (2010) Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature 468: 709–712.
- 23. Li L, Jose J, Xiang Y, Kuhn RJ, Rossmann MG (2010) Structural changes of envelope proteins during alphavirus fusion. Nature 468: 705–708.
- 24. Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, et al. (2009) Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis 200: 516–523.
- 25. Chopra A, Anuradha V, Lagoo-Joshi V, Kunjir V, Salvi S, et al. (2008) Chikungunya virus aches and pains: an emerging challenge. Arthritis Rheum 58: 2921–2922.
- 26. Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, Das T, Li-Pat-Yuen G, et al. (2010) Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol 184: 5914–5927.
- 27. Labadie K, Larcher T, Joubert C, Mannioui A, Delache B, et al. (2010) Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest 120: 894–906.
- 28. Warter L, Lee CY, Thiagarajan R, Grandadam M, Lebecque S, et al. (2011) Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency. J Immunol 186: 3258–3264.
- 29. Grob P, Schijns VE, van den Broek MF, Cox SP, Ackermann M, et al. (1999) Role of the individual interferon systems and specific immunity in mice in controlling systemic dissemination of attenuated pseudorabies virus infection. J Virol 73: 4748–4754.
- 30. Couderc T, Chretien F, Schilte C, Disson O, Brigitte M, et al. (2008) A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 4: e29.
- 31. Law M, Hollinshead R, Smith GL (2002) Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread. J Gen Virol 83: 209–222.
- 32. Mothes W, Sherer NM, Jin J, Zhong P (2010) Virus cell-to-cell transmission. J Virol 84: 8360–8368.
- 33. Schroder C, Keil GM (1999) Bovine herpesvirus 1 requires glycoprotein H for infectivity and direct spreading and glycoproteins gH(W450) and gB for glycoprotein D-independent cell-to-cell spread. J Gen Virol 80(Pt 1): 57–61.
- 34. Sattentau Q (2008) Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol 6: 815–826.
- 35. Hahon N, Zimmerman WD (1970) Chikungunya virus infection of cell monolayers by cell-to-cell and extracellular transmission. Appl Microbiol 19: 389–391.
- 36. Meyer WJ, Johnston RE (1993) Structural rearrangement of infecting Sindbis virions at the cell surface: mapping of newly accessible epitopes. J Virol 67: 5117–5125.
- 37. Pence DF, Davis NL, Johnston RE (1990) Antigenic and genetic characterization of Sindbis virus monoclonal antibody escape mutants which define a pathogenesis domain on glycoprotein E2. Virology 175: 41–49.
- 38. Stec DS, Waddell A, Schmaljohn CS, Cole GA, Schmaljohn AL (1986) Antibody-selected variation and reversion in Sindbis virus neutralization epitopes. J Virol 57: 715–720.
- 39. Vrati S, Fernon CA, Dalgarno L, Weir RC (1988) Location of a major antigenic site involved in Ross River virus neutralization. Virology 162: 346–353.
- 40. Agapov EV, Razumov IA, Frolov IV, Kolykhalov AA, Netesov SV, et al. (1994) Localization of four antigenic sites involved in Venezuelan equine encephalomyelitis virus protection. Arch Virol 139: 173–181.
- 41. Hunt AR, Frederickson S, Maruyama T, Roehrig JT, Blair CD (2010) The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity. PLoS Negl Trop Dis 4: e739.
- 42. Johnson BJ, Brubaker JR, Roehrig JT, Trent DW (1990) Variants of Venezuelan equine encephalitis virus that resist neutralization define a domain of the E2 glycoprotein. Virology 177: 676–683.
- 43. Coffey LL, Vignuzzi M (2011) Host alternation of chikungunya virus increases fitness while restricting population diversity and adaptability to novel selective pressures. J Virol 85: 1025–1035.
- 44. Flynn DC, Meyer WJ, Mackenzie JM Jr, Johnston RE (1990) A conformational change in Sindbis virus glycoproteins E1 and E2 is detected at the plasma membrane as a consequence of early virus-cell interaction. J Virol 64: 3643–3653.
- 45. Drake JW, Holland JJ (1999) Mutation rates among RNA viruses. Proc Natl Acad Sci U S A 96: 13910–13913.
- 46. Holland J, Spindler K, Horodyski F, Grabau E, Nichol S, et al. (1982) Rapid evolution of RNA genomes. Science 215: 1577–1585.
- 47. Sanjuan R, Nebot MR, Chirico N, Mansky LM, Belshaw R (2010) Viral mutation rates. J Virol 84: 9733–9748.
- 48. Coffey LL, Vasilakis N, Brault AC, Powers AM, Tripet F, et al. (2008) Arbovirus evolution in vivo is constrained by host alternation. Proc Natl Acad Sci U S A 105: 6970–6975.
- 49. Jerzak G, Bernard KA, Kramer LD, Ebel GD (2005) Genetic variation in West Nile virus from naturally infected mosquitoes and birds suggests quasispecies structure and strong purifying selection. J Gen Virol 86: 2175–2183.
- 50. Weaver SC, Rico-Hesse R, Scott TW (1992) Genetic diversity and slow rates of evolution in New World alphaviruses. Curr Top Microbiol Immunol 176: 99–117.
- 51. Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, et al. (2008) Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47: 17–24.
- 52. Johnson DC, Huber MT (2002) Directed egress of animal viruses promotes cell-to-cell spread. J Virol 76: 1–8.
- 53. Bernard KA, Klimstra WB, Johnston RE (2000) Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276: 93–103.
- 54. Klimstra WB, Ryman KD, Johnston RE (1998) Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J Virol 72: 7357–7366.
- 55. Ryman KD, Gardner CL, Burke CW, Meier KC, Thompson JM, et al. (2007) Heparan sulfate binding can contribute to the neurovirulence of neuroadapted and nonneuroadapted Sindbis viruses. J Virol 81: 3563–3573.
- 56. Plaskon NE, Adelman ZN, Myles KM (2009) Accurate strand-specific quantification of viral RNA. PLoS One 4: e7468.